TFA Therapeutics (RAJAF) Gross Profit (2020 - 2023)

TFA Therapeutics has reported Gross Profit for 4 years, with the latest figure at $284660.0 in Q4 2023.

• On a quarterly basis, Gross Profit rose 367.97% year-over-year to $284660.0 in Q4 2023; TTM through Dec 2023 was $96290.0, a N/A change from a year earlier, with the FY2025 full-year figure at $760741.0, down 16.08% from the prior year.
• Gross Profit was $284660.0 for Q4 2023 at TFA Therapeutics, up from -$106230.0 in the prior quarter.
• The five-year high for Gross Profit was $284660.0 in Q4 2023, with the low at -$176212.0 in Q4 2021.
• Average Gross Profit over 4 years is $24072.5, with a median of -$6079.0 recorded in 2020.
• The sharpest annual moves came in 2021 and 2023: Gross Profit sank 287.32% in 2021, then soared 367.97% in 2023.
• Over 4 years, Gross Profit stood at $94072.0 in 2020, then tumbled by 287.32% to -$176212.0 in 2021, then jumped by 39.71% to -$106230.0 in 2022, then surged by 367.97% to $284660.0 in 2023.
• The last three Gross Profit figures came in at $284660.0 (Q4 2023), -$106230.0 (Q4 2022), and -$176212.0 (Q4 2021), per Business Quant data.